The Mitochondrial Health Stack: A Research Guide to Longevity Supplements

What this guide covers

Vector Sapiens is the SciRouter human longevity formula — a daily stack built around four compounds with a substantial peer-reviewed research base for mitochondrial function, autophagy, and cellular senescence: urolithin A, calcium alpha-ketoglutarate (Ca-AKG), spermidine, and fisetin. This guide walks through what each one is, how it works mechanically, what the published human and animal research actually shows, and where the limitations are.

Two notes on language before we begin. First, this is informational content. We use structure/function language throughout — "studied for", "associated with", "plays a role in". This guide is not medical advice; the regulatory disclaimer printed at the foot of every article spells out the limits, and if you are managing a specific health condition or are on prescription pharmaceuticals, consult a licensed physician before starting any supplement.

Second, we cite. Every scientific claim in this article points to a peer-reviewed PubMed-indexed source. Citations are numbered in the order they first appear, with the full reference list at the foot of the article. If a claim is not cited, it is general background. If we cannot cite something, we do not say it.

Why mitochondria matter for healthspan

Mitochondria are the small organelles inside almost every human cell that convert nutrients into ATP — the chemical energy that powers everything from muscle contraction to immune-cell signaling. The current scientific picture of aging gives them a central role: mitochondrial dysfunction is one of the established hallmarks of aging, alongside loss of proteostasis, cellular senescence, stem-cell exhaustion, and a handful of others. A 2024 review in Sports Medicine explicitly framed mitochondria as nutritional targets for maintaining muscle health and physical function during aging ¹.

What does mitochondrial decline with age look like in practice? Cell biology research describes accumulating mitochondrial damage (oxidative damage to mitochondrial DNA and inner-membrane proteins), reduced mitochondrial biogenesis (the body makes fewer new mitochondria), and slower mitophagy (the body removes damaged ones less efficiently). The cellular consequence is a population of mitochondria that includes more dysfunctional ones — less efficient ATP production, more oxidative byproducts.

The framing in the longevity literature is that this decline is a tractable target. Reviews of caloric-restriction mimetics — compounds that mimic some of the effects of caloric restriction — discuss several molecular axes through which interventions can plausibly slow mitochondrial decline ². Cardiovascular research has independently emphasized autophagy as a mediator of cardiovascular aging ³, and a 2025 roadmap in Nature Reviews Cardiology synthesizes the broader cardiovascular-aging research program ⁴.

The four compounds in Vector Sapiens are each studied for one or more of these mitochondrial-quality axes: mitophagy (urolithin A), Krebs-cycle intermediates and methylation reactions (Ca-AKG), autophagy via polyamine signaling (spermidine), and clearance of senescent cells that contribute to chronic low-grade inflammation (fisetin).

Urolithin A — mitophagy activator

Urolithin A is a metabolite. Specifically, it is the metabolite that gut bacteria produce when they encounter ellagitannins — the polyphenols in pomegranates, walnuts, and some berries. The interesting biochemistry is that not everyone's gut microbiome produces urolithin A from ellagitannin precursors; in some individuals, the conversion is partial or absent. A 2022 mechanistic review describes urolithins as gut-microbial metabolites of ellagitannins and details their biological activities ⁵. Direct supplementation with urolithin A bypasses the microbiome-dependence problem.

The compound entered the longevity literature in 2016, when a Nature Medicine paper described urolithin A as inducing mitophagy and prolonging lifespan in C. elegans, alongside increased muscle function in rodents ⁶. The mechanism, summarized in subsequent reviews, is that urolithin A activates mitophagy — the selective autophagy of damaged mitochondria ⁷⁸. Old cells accumulate damaged mitochondria; mitophagy is the cellular routine that cleans them up; urolithin A is studied for its role in enhancing this routine.

Then the human data started arriving. The first published human trial was Andreux et al. 2019 in Nature Metabolism — a randomized, double-blind, placebo-controlled study of urolithin A at 250 mg, 500 mg, and 1000 mg daily over 28 days in older adults ⁹. The trial reported no significant adverse-event differences from placebo and described a molecular signature consistent with improved mitochondrial and cellular health.

In 2022, two longer trials reported functional outcomes. Liu et al. in JAMA Network Open randomized older adults to four months of urolithin A vs. placebo and reported improvements in muscle endurance and biomarkers of mitochondrial health ¹⁰. Singh et al. in Cell Reports Medicine ran a similar four-month trial in middle-aged adults at 500 mg/day, reporting improvements in muscle strength, exercise performance, and mitochondrial-health biomarkers ¹¹.

The field has continued to expand. A 2024 systematic review in Ageing Research Reviews synthesized the human urolithin A literature ¹². A 2023 Cureus scoping review covered urolithin A's potential as an agent for age-related research ¹³. A 2024 trial in heart-failure patients with reduced ejection fraction explored functional outcomes ¹⁴. A 2025 study in highly trained runners examined performance and recovery effects ¹⁵. A 2025 Nature Aging trial reported on urolithin A's effects on age-related immune decline markers ¹⁶.

Dose: the most-studied human dose is 500 mg once daily. Andreux 2019 also tested 250 mg and 1000 mg in 28-day windows ⁹. Longer-duration trials (Liu, Singh, several follow-ups) have used 500 mg or 1000 mg ¹⁰¹¹.

Calcium alpha-ketoglutarate (Ca-AKG) — Krebs-cycle intermediate

Alpha-ketoglutarate (AKG) is a Krebs-cycle intermediate. The Krebs cycle is the central metabolic pathway by which cells extract energy from glucose, fatty acids, and amino acids; AKG sits at a hub position, intersecting with amino-acid metabolism and a class of dioxygenase enzymes that regulate DNA and histone methylation.

The supplement form, calcium alpha-ketoglutarate, is calcium salt of AKG; the calcium serves a stability role and adds a small amount of supplemental calcium. The compound is endogenous — your cells produce and consume AKG constantly. Supplementation studies the effect of dietary AKG on circulating and tissue levels.

The mouse data is striking. A 2020 study in Cell Metabolism reported that AKG, administered late in life, extended median lifespan and compressed morbidity — meaning the treated mice not only lived longer but spent more of their remaining life healthy rather than declining ¹⁷. An earlier paper in Nature established a mechanism: AKG extends lifespan in C. elegans by inhibiting ATP synthase and TOR signaling ¹⁸. A Nature Communications paper in 2020 described AKG's effects on age-related osteoporosis in mice via regulation of histone methylations ¹⁹, pointing at a mechanism that connects AKG's metabolic role to epigenetic regulation.

The human picture is younger. A 2022 review in Trends in Endocrinology and Metabolism summarized AKG dietary supplementation research in humans and laid out the open questions ²⁰. Long-term human lifespan-extension data does not exist; structure/function research is ongoing. We mention this directly because it matters: the most exciting AKG data is in mice, not yet in humans.

Dose: the published mouse studies used food-supplementation doses that translate (approximately) to ~1–2 g/day in humans. Most human supplementation protocols dose Ca-AKG in the 1–3 g/day range, often split across the day.

Spermidine — autophagy via polyamines

Spermidine is a polyamine. Polyamines are small organic molecules involved in a wide range of cellular processes; spermidine specifically is studied for its role in inducing autophagy — the cellular process of recycling damaged proteins and organelles. A 2018 Science review by Madeo et al. covered spermidine in health and disease and synthesized the mechanism literature ²¹. The same group's 2019 Cell Metabolism review framed spermidine and related polyamines as part of the broader class of caloric-restriction mimetics ² — compounds that mimic some of the molecular effects of caloric restriction without the food deprivation.

The mechanistic case is reasonably strong: induced autophagy is associated with healthspan extension across model systems, and polyamine biosynthesis declines with age. The translational case in humans is less developed than urolithin A's — there are far fewer randomized trials. The literature is largely mechanistic and observational. We include spermidine in Vector Sapiens because the mechanistic story is strong and the safety profile is established, with appropriate framing of what is (and is not) settled.

Dose: typical supplementation in human studies ranges from 1 mg to 15 mg per day, with food sources (wheat germ, aged cheese, fermented foods) providing comparable amounts dietarily.

Fisetin — senolytic flavonoid

Fisetin is a flavonoid found in strawberries and other plants. The longevity-research interest in fisetin centers on its description as a senolytic — a compound that selectively clears senescent cells. Senescent cells are cells that have stopped dividing but remain metabolically active and secrete inflammatory signals (the senescence-associated secretory phenotype, or SASP). They accumulate with age and contribute to chronic low-grade inflammation; clearing them in animal models is associated with improved healthspan markers.

The pivotal paper is Yousefzadeh et al. 2018 in EBioMedicine, which described fisetin as a senotherapeutic that extended health and lifespan in aged mice ²². Subsequent senolytic-class work has continued to study fisetin and related compounds — for example, a 2021 Science paper reported that senolytics reduced coronavirus-related mortality in old mice ²³.

Human translational data for fisetin specifically is early-stage. The cellular mechanism is established; the dose-response curve in humans is an active research question. We dose fisetin in Vector Sapiens at a modest level consistent with the published mouse-to-human dose-translation literature.

Dose: published mouse experiments translate (approximately) to ~10–20 mg/kg in humans; commercial supplementation typically dose much lower for daily use. Senolytic dosing protocols in research settings have sometimes used short-duration high-dose "hit and run" approaches rather than continuous daily intake.

A note on NMN

Vector Sapiens does not include NMN. NMN — nicotinamide mononucleotide — is the most-published of the NAD+-precursor compounds; the human research base includes a randomized middle-aged-adult safety study in GeroScience ²⁴ and a 2021 Science paper reporting that NMN increased muscle insulin sensitivity in prediabetic women ²⁵. NMN raises NAD+ levels via the salvage pathway and is studied for metabolic and cardiovascular endpoints.

We mention this because honest comparison helps people choose: NMN and the Vector Sapiens stack target different cellular axes. NAD+ precursors target NAD+ availability for sirtuin and PARP signaling. Vector Sapiens targets mitophagy, autophagy, Krebs-cycle metabolism, and senescent-cell clearance. The two approaches are complementary, not redundant — many of the research summaries explicitly cover both ²⁶²⁷.

If you are weighing NMN versus a mitochondrial-stack approach, the most useful framing is "what cellular mechanism do I want to support, with what published evidence base?" rather than "which compound is best."

Glycine and other supporting research

Glycine deserves a brief mention. A 2023 Ageing Research Reviews paper summarized the glycine-and-aging research base ²⁸ — a useful read for understanding why some longevity protocols include glycine as a complementary amino-acid component. Glycine is not part of Vector Sapiens but is consistent with the broader "support mitochondrial and glutathione-related metabolic pathways" philosophy.

How to think about supplement stacking

A few honest framings.

First, no supplement compound — not one — is a substitute for the foundational interventions: sleep, exercise (especially resistance training), high-quality food, alcohol moderation, sun exposure for vitamin D, and stress management. The longevity-supplement literature is most useful as a layer on top of those foundations, not in place of them.

Second, single-compound studies do not perfectly predict multi-compound effects. The published RCTs cited above tested compounds individually. Real-world supplementation often involves stacks; the interactions are mostly unstudied. We dose Vector Sapiens at levels consistent with single-compound research and avoid extreme stacking, but the literature does not (yet) tell us with confidence how four compounds interact at human doses over years.

Third, the research base is most developed for muscle, mitochondrial-health biomarker, and exercise-performance endpoints — particularly for urolithin A. Other endpoints — cognition, cardiovascular, immune — have promising mechanism papers and individual trials, but smaller bodies of confirmed human evidence.

Fourth, age, sex, and baseline status matter. The published urolithin A trials have largely been in middle-aged and older adults; the AKG mouse data is most striking when AKG is started late in life. Younger adults in their twenties may see less benefit from compounds whose mechanism targets age-related decline.

What the research does not say

We want to be explicit about the things we cannot honestly claim.

• We cannot honestly claim that any of these compounds extends human lifespan. Direct lifespan-extension evidence in humans requires multi-decade trials that have not been completed for any supplement.
• These are dietary supplements, not pharmaceuticals. Structure/function research is the right frame for understanding what they do; therapeutic claims are not.
• We cannot honestly extrapolate animal-model effect sizes to humans. Mouse studies often use doses that are much higher (mg/kg) than human supplementation protocols, and species differences in metabolism are real.
• We cannot honestly assume that improvements in surrogate biomarkers — mitochondrial-DNA copy number, walking distance, NAD+ levels — translate directly to improvements in healthspan or lifespan, even when the mechanism story is plausible.

A reasonable consumer framing: the published evidence supports the hypothesis that these compounds support specific cellular and tissue functions; the published evidence does not yet support strong claims about long-term health outcomes.

Want to support this research direction?

The Vector Sapiens formula is built around the four compounds described above, dosed at levels consistent with the published research base, manufactured in NSF/cGMP-compliant facilities, and labeled with third-party potency assay data. See the Vector Sapiens product overview for ingredient amounts, manufacturing details, and the waitlist.